Also trades as: BRIBF (OTC) · $vol 0M
2137.HK HKSE
Brii Biosciences Limited
1W: -3.4%
1M: -6.0%
3M: -24.6%
YTD: -44.9%
1Y: -59.6%
3Y: -75.5%
HK$0.86 ($0.11)
-0.01 (-0.58%)
Weekly Expected Move ±4.0%
HK$1
HK$1
HK$1
HK$1
HK$1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$373M
+37.2% ▲
Capital Expenditures
$3M
+93.5% ▲
5Y CAGR: -33.1%
Free Cash Flow
-$376M
+41.6% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$220K
+81.1% ▲
Net Change in Cash
$514M
+173.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$1.3B | -$4.2B | -$490M | -$184M | -$512M |
| Depreciation & Amort. | $14M | $17M | $17M | $16M | $9M |
| Stock-Based Comp. | $29M | $79M | $78M | $64M | $16M |
| Change in Working Capital | $471M | -$334M | -$77M | -$121M | -$50M |
| Other Non-Cash Items | $350M | $3.6B | -$24M | -$369M | $165M |
| Operating Cash Flow | -$404M | -$879M | -$496M | -$594M | -$373M |
| — Investing Activities — | |||||
| Capital Expenditures | $0 | -$1M | -$139M | $0 | -$3M |
| Acquisitions (Net) | $0 | $2M | $0 | $56M | $0 |
| Investment Purchases | -$196M | -$500M | -$2.1B | -$3.5B | -$1.9B |
| Investment Sales | $154M | $20M | $775M | $3.3B | $2.8B |
| Other Investing | -$1M | $3M | $33M | $58M | -$6M |
| Investing Cash Flow | -$44M | -$476M | -$1.4B | -$104M | $895M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$7M | -$10M | -$9M | -$10M | -$7M |
| Stock Repurchased | $0 | $0 | -$678K | -$1M | -$220K |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$5M | -$88M | $7M | -$315K | -$2M |
| Financing Cash Flow | $657M | $3.2B | -$3M | -$11M | -$9M |
| Net Change in Cash | $155M | $1.8B | -$1.7B | -$701M | $514M |
| Cash End of Period | $1.0B | $2.9B | $1.2B | $490M | $1.0B |
| Free Cash Flow | -$404M | -$880M | -$636M | -$644M | -$376M |